Ruth O'Regan
University of Wisconsin-Madison
CancerInternal medicineEndocrinologyPathologyOncologyStage (cooking)Hormone receptorMetastatic breast cancerChemotherapyTamoxifenEverolimusTrastuzumabTriple-negative breast cancerPopulationGynecologyCancer researchBreast cancerMedicineEstrogen receptorPI3K/AKT/mTOR pathwayBiology
259Publications
55H-index
8,696Citations
Publications 258
Newest
#1Marina N. SharifiH-Index: 10
#2Serena K. WolfeH-Index: 1
Last. Ruth O'ReganH-Index: 55
view all 8 authors...
Source
#2Jinfeng Chen (CAS: Chinese Academy of Sciences)H-Index: 2
Combining cyclin-dependent kinase (CDK) inhibitors with endocrine therapy improves outcomes for patients with metastatic estrogen receptor-positive breast cancer but its value in earlier-stage patients is unclear. We examined evolutionary trajectories of early-stage breast cancer tumors, using single-cell RNA sequencing of serial biopsies from the FELINE clinical trial of endocrine therapy (letrozole) alone or combined with the CDK inhibitor ribociclib. Despite differences in subclonal diversity...
Source
Source
Source
#1Y-S LuH-Index: 8
#2N.S. El SaghirH-Index: 11
Last. S-A ImH-Index: 9
view all 14 authors...
Source
#1William J. Gradishar (NU: Northwestern University)H-Index: 68
#2Meena S. Moran (Yale Cancer Center)H-Index: 34
Last. Rashmi Kumar (National Comprehensive Cancer Network)H-Index: 18
view all 38 authors...
The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer-focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, r...
3 CitationsSource
#1Sara M. Tolaney (Harvard University)H-Index: 47
#2Kevin Kalinsky (Emory University)H-Index: 4
Last. Sami DiabH-Index: 19
view all 18 authors...
Purpose As monotherapies, eribulin (chemotherapy) and pembrolizumab (immunotherapy) have shown promise for patients with metastatic triple-negative breast cancer (mTNBC). This phase 1b/2 study examined eribulin plus pembrolizumab as a potential mTNBC treatment in first-line and later-line settings. Experimental design In this open-label, single-arm, phase 1b/2 study, eligible patients had mTNBC, measurable disease, and {less than or equal to}2 prior systemic anticancer therapies in the metastati...
3 CitationsSource
#1Lowell B. Anthony (Markey Cancer Center)H-Index: 3
#2George F. Atweh (UNM: University of New Mexico)
Last. Julie M. Vose (UNMC: University of Nebraska Medical Center)H-Index: 106
view all 14 authors...
The role of clinical researchers is vital to cancer progress. The teaching, research, and leadership roles that academic oncologists hold need to be accounted for and appropriately compensated. National metrics are currently inexistent, but are necessary to move the oncology research field forward. Clinical research and routine clinical care must be harmoniously integrated without competing. This article reviews the national landscape of clinical cancer research and proposes a call for action.
Source
#1Marina N. SharifiH-Index: 10
#2Jamie M. SpergerH-Index: 12
Last. Joshua M. LangH-Index: 17
view all 8 authors...
Source
#1Yee Chung ChengH-Index: 9
#2Ruth O'ReganH-Index: 55
Last. Kari B. WisinskiH-Index: 21
view all 10 authors...
Source